National Comprehensive Cancer Network. Clinical practice guidelines in oncology: non-small cell lung cancer. v.5.2021. nccn.org. Accessed August 23, 2021.
Alexander M, Kim SY, Cheng H. Update 2020: management of non-small cell lung cancer. Lung. 2020;198:897-907.
Detterbeck FC, Boffa DJ, Kim AW, et al. The eighth edition lung cancer stage classification. Chest. 2017;151:193-203.
Goldstraw P, Chansky K, Crowley J, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM Classification for lung cancer. J Thorac Oncol. 2016;11:39-51.
Neppl C, Keller MD, Scherz A, et al. Comparison of the 7th and 8th Edition of the UICC/AJCC TNM staging system in primary resected squamous cell carcinomas of the lung—a single center analysis of 354 cases. Front Med (Lausanne). 2019;6:196.
Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008;26:3552-3559.
Wu YL, Tsuboi M, He J, et al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2020;383:1711-1723.
Midha A, Dearden S, McCormack R. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). Am J Cancer Res. 2015;5:2892-2911.
Lewis J, Gillaspie EA, Osmundson EC, et al. Before or after: evolving neoadjuvant approaches to locally advanced non-small cell lung cancer. Front Oncol. 2018;8:5.
Felip E, Rosell R, Maestre JA, et al. Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer. J Clin Oncol. 2010;28:3138-3145.
Hellman MD. Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. Lancet Oncol. 2014;15:e42-e50.
McElnay P, Lim E. Adjuvant or neoadjuvant chemotherapy for NSCLC. J Thorac Dis. 2014;6(suppl 2):S224-S227.
Yuan M, Huang LL, Chen JH, et al. The emerging treatment landscape of targeted therapy in non-small-cell lung cancer. Signal Transduct Target Ther. 2019;4:61.
Forde PM, Spicer J, Lu S, et al. Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment (tx) for resectable (IB-IIIA) non-small cell lung cancer (NSCLC) in the phase 3 CheckMate 816 trial. Presented at: 2021 American Association for Cancer Research Annual Meeting; April 10-15 and May 17-21, 2021. Abstract CT003.
Cottrell TR, Thompson ED, Forde PM, et al. Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC). Ann Oncol. 2018;29:1853-1860.
Baden J, Chang H, Greeenawalt DM, et al. Comparison of platforms for determining tumor mutational burden (TMB) from blood samples in patients with non-small cell lung cancer (NSCLC). Presented at: 2019 European Society for Medical Oncology Congress; September 27 - October 1, 2019. Abstract 2736.
ClinicalTrials.gov. Efficacy and safety of pembrolizumab (MK-3475) with platinum doublet chemotherapy as neoadjuvant/adjuvant therapy for participants with resectable stage II, IIIA, and resectable IIIB (T3-4N2) non-small cell lung cancer (MK-3475-671/KEYNOTE-671). clinicaltrials.gov/ct2/show/NCT03425643. Accessed August 23, 2021.
ClinicalTrials.gov. A study of neoadjuvant atezolizumab plus chemotherapy versus placebo plus chemotherapy in patients with resectable stage II, IIIA, or select IIIB non-small cell lung cancer (IMpower030). clinicaltrials.gov/ct2/show/NCT03456063. Accessed August 23, 2021.
ClinicalTrials.gov. A study of neoadjuvant/adjuvant durvalumab for the treatment of patients with resectable non-small cell lung cancer (AEGEAN). clinicaltrials.gov/ct2/show/NCT03800134. Accessed August 23, 2021.
ClinicalTrials.gov. A study of neoadjuvant chemotherapy plus nivolumab versus neoadjuvant chemotherapy plus placebo, followed by surgical removal and adjuvant treatment with nivolumab or placebo for participants with surgically removable early stage non-small-cell lung cancer. clinicaltrials.gov/ct2/show/NCT04025879. Accessed August 23, 2021.
Wakelee HA, Altorki NK, Zhou C, et al. IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC). Presented at: 2021 American Society of Clinical Oncology Annual Meeting; June 4-8, 2021. Abstract 8500.
US Food and Drug Administration. Clinical trial endpoints for the approval of cancer drugs and biologics: guidance for industry. fda.gov/media/71195/download. Accessed August 23, 2021.
Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;282:41-50.
Topalian SL, Hodi FS, Brahmer JR. Five-year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or non–small cell lung cancer treated with nivolumab. JAMA Oncol. 2019;5:1411-1420.
ClinicalTrials.gov. Study to assess safety and efficacy of atezolizumab (MPDL3280A) compared to best supportive care following chemotherapy in patients with lung cancer [IMpower010]. clinicaltrials.gov/ct2/show/NCT02486718. Accessed August 23, 2021.
ClinicalTrials.gov. Nivolumab after surgery and chemotherapy in treating patients with stage IB-IIIA non-small cell lung cancer (an ALCHEMIST treatment trial) (ANVIL). clinicaltrials.gov/ct2/show/NCT02595944. Accessed August 23, 2021.
ClinicalTrials.gov. Study of pembrolizumab (MK-3475) vs placebo for participants with non-small cell lung cancer after resection with or without standard adjuvant therapy (MK-3475-091/KEYNOTE-091) (PEARLS). clinicaltrials.gov/ct2/show/NCT02504372. Accessed August 23, 2021.
ClinicalTrials.gov. Double blind placebo controlled study of adjuvant MEDI4736 in completely resected NSCLC. clinicaltrials.gov/ct2/show/NCT02273375. Accessed August 23, 2021.
ClinicalTrials.gov. Integration of immunotherapy into adjuvant therapy for resected NSCLC: ALCHEMIST Chemo-IO (ACCIO). clinicaltrials.gov/ct2/show/NCT04267848. Accessed August 23, 2021.